PAH News

June 12, 2017June 12, 2017

Pulmonary Hypertension Therapy Developer MannKind Retains Biopharma Financing Specialist

News, PAH News

MannKind Corporation, which is developing the pulmonary arterial hypertension (PAH) therapy Treprostinil Technosphere, has retained the biopharmaceutical financing specialist Locust Walk to help it raise capital for Treprostinil and other projects. Locust Walk ... Read more

June 9, 2017June 9, 2017

Sixty Pulmonary Hypertension Patients Receive Implanted-pump Therapy-delivery Systems

News, PAH News

Researchers implanted a long-term, intravenous therapy-delivery system consisting of internal pumps and catheters in 60 pulmonary arterial hypertension (PAH) patients, according to a clinical trial. The IV infusion system, developed ... Read more

June 7, 2017June 7, 2017

Short Survival of Only 4 Years Still Characterizes Systemic Sclerosis Patients with PAH, Australian Study Finds

News, PAH News

The average systemic sclerosis (SSc) patient burdened with pulmonary arterial hypertension (PAH) lives only four years after diagnosis, finds an Australian study, “Survival and quality of life in incident systemic ... Read more

June 1, 2017June 1, 2017

Reviva Secures $4.8 Million in Financing to Keep Developing Pulmonary Hypertension Therapy

News, PAH News

Reviva Pharmaceuticals has obtained $4.8 million in financing to keep developing its treatments for pulmonary arterial hypertension (PAH) and other diseases. The financing, in the form of a loan that can ... Read more

May 23, 2017May 23, 2017

Pulmonary Hypertension Association Accredits Three More Regional Clinics

News, PAH News, PH News

The Pulmonary Hypertension Association has accredited three more regional clinics that have demonstrated an ability to deliver high-quality care to pulmonary hypertension (PH) patients. The three are the French Hospital ... Read more

May 22, 2017May 22, 2017

Two Pulmonary Arterial Hypertension Experts to Speak at Arena-sponsored Event in New York

News, PAH News

Two pulmonary arterial hypertension experts will speak to investment professionals at a gathering in New York this week that Arena Pharmaceuticals is holding. Arena will also discuss ralinepag (APD811), a treatment it ... Read more

May 19, 2017May 19, 2017

Exercise-capacity Builder Tracleer May Decrease Impact of Two Other PAH Therapies, Revatio and Adcirca

News, PAH News

Tracleer, which improves pulmonary arterial hypertension patients’ exercise capability, may decrease the effectives of two other PAH treatments, Revatio and Adcirca, according to a study. One of the problems with ... Read more

May 17, 2017May 17, 2017

INOpulse System as PH Treatment Moves into ‘Speedier’ Phase 3 Clinical Trial

News, PAH News, PH News

Bellerophon Therapeutics recently offered an update on the company’s INOpulse system, as part of its first quarter 2017 financial report. The system is in clinical testing as a therapy for three types of pulmonary hypertension. The ... Read more

May 16, 2017May 16, 2017

Patient Enrollment Complete in Phase 2 Trial of Ubenimex for Pulmonary Arterial Hypertension

News, PAH News

Patient enrollment is complete in a Phase 2 clinical trial of ubenimex as an add-on to standard therapy for pulmonary arterial hypertension (PAH), according to ubenimex’s developer, Eiger BioPharmaceuticals. Sixty-one patients at ... Read more

May 15, 2017May 15, 2017

Patients Being Enrolled for Phase 2 and 3 Trials of Bardoxolone Methyl to Treat PAH and PH

News, PAH News, PH News

Reata Pharmaceuticals is enrolling participants for two ongoing clinical trials of bardoxolone methyl as a treatment for pulmonary arterial hypertension (PAH) and pulmonary hypertension (PH) caused by an underlying interstitial ... Read more